Tumor-associated antigen peptide–MHC complex

The tumor-associated antigen peptide–major histocompatibility complex (pMHC) complex is a molecular structure formed when a short protein fragment derived from a tumor-specific or overexpressed protein (“tumor-associated antigen”) binds within the groove of an MHC molecule. This assembly is displayed on the surface of cancer cells and recognized by cytotoxic CD8+ T lymphocytes via their T cell receptor. The specificity and diversity of both peptides and MHC alleles underlie individual differences in anti-tumor immunity. The process involves proteasomal degradation of intracellular proteins, transport into the endoplasmic reticulum, editing/selection for high-affinity binding peptides, loading onto class I or II MHC molecules, and surface presentation[1][2][3][4]. Defects in this pathway are common mechanisms for tumors to evade immune surveillance. Therapeutic strategies—including vaccines, adoptive cellular therapies using engineered receptors targeting defined pMHC complexes, and checkpoint blockade—aim to exploit or restore effective recognition at this interface.\n\nThis target is central to modern cancer immunotherapy because it represents both an essential mechanism for adaptive immunity against tumors as well as a potential point for therapeutic intervention[3][4].

Other names

Peptide–MHC complexTumor antigen–MHC complexpMHC (peptide–major histocompatibility complex)Tumor-associated peptide–HLA complex (in humans, HLA is the human MHC)

Recognition by cytotoxic CD8+ T lymphocytes leading to targeted killing of tumor cells[4]; Modulation by immunotherapies that enhance or restore immune detection of tumor antigens presented in the context of MHC molecules[4]